Preliminary experience with porcine intestinal submucosa (CorMatrix) for valve reconstruction in congenital heart disease: histologic evaluation of explanted valves.

OBJECTIVE We compared the histologic findings in explanted CorMatrix (9 patients) and autologous pericardium (9 patients) used for valvuloplasty of the aortic (7 patients) and/or mitral (11 patients) valve in patients with congenital heart defects. METHODS We used standard tissue stains and immunohistochemistry to identify the inflammatory cell type. RESULTS CorMatrix was associated with an intense inflammatory response in the surrounding native tissue, extending into CorMatrix in 8 of 9 cases, continuing to the longest follow-up point (9 months). The typical response included macrophages and giant cells in contact with the material, surrounded by lymphocytes, macrophages, plasma cells, and eosinophils. The thickness of the residual CorMatrix material was 280 to 300 μm, similar to the nominal thickness at implantation and unrelated to the implantation duration. Only at the longest follow-up interval was any significant resorption of CorMatrix material evident. A neointima had formed on the surface of CorMatrix, increasing in thickness with the period in situ. Mild cellular infiltration of CorMatrix was noted in all cases; however, in no case, did it appear that CorMatrix was being remodeled into tissue resembling a 3-layered native valve. In contrast, a near absence of any inflammatory reaction was seen and no eosinophilia associated with autologous pericardium was present, irrespective of the duration in situ. Furthermore, we observed more tissue infiltration, remodeling, vascularization, and neointima formation with autologous pericardium. CONCLUSIONS Although CorMatrix used for valve repair induced an intense inflammatory response, little or no remodeling to form tissue resembling a 3-layered native valve was seen at ≤9 months after implantation.

[1]  A. Carpentier,et al.  Valve extension with glutaraldehyde-preserved autologous pericardium. Results in mitral valve repair. , 1991, The Journal of thoracic and cardiovascular surgery.

[2]  Klod Kokini,et al.  Morphologic study of small intestinal submucosa as a body wall repair device. , 2002, The Journal of surgical research.

[3]  F. Rosso,et al.  From Cell–ECM interactions to tissue engineering , 2004, Journal of cellular physiology.

[4]  S. Badylak,et al.  Increased myocyte content and mechanical function within a tissue-engineered myocardial patch following implantation. , 2009, Tissue engineering. Part A.

[5]  M. Si,et al.  Short-term experience of porcine small intestinal submucosa patches in paediatric cardiovascular surgery. , 2013, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[6]  S. Shohet,et al.  Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. , 1988, The Journal of biological chemistry.

[7]  R. Matheny,et al.  Remodeling of extracellular matrix patch used for carotid artery repair. , 2012, The Journal of surgical research.

[8]  Buddy D Ratner,et al.  Surface characterization of extracellular matrix scaffolds. , 2010, Biomaterials.

[9]  George P McCabe,et al.  Extracellular matrix bioscaffolds for orthopaedic applications. A comparative histologic study. , 2006, The Journal of bone and joint surgery. American volume.

[10]  D. Cooper,et al.  Variability of anti‐αGal antibodies in human serum and their relation to serum cytotoxicity against pig cells , 1994 .

[11]  K. Fung,et al.  Leukocyte inflammatory response in a rat urinary bladder regeneration model using porcine small intestinal submucosa scaffold. , 2009, Tissue engineering. Part A.

[12]  R. Matheny,et al.  Porcine small intestine submucosa as a pulmonary valve leaflet substitute. , 2000, The Journal of heart valve disease.

[13]  M. Pozzi,et al.  Preliminary experience in the use of an extracellular matrix to repair congenital heart diseases. , 2011, Interactive cardiovascular and thoracic surgery.

[14]  George P McCabe,et al.  Macrophage phenotype and remodeling outcomes in response to biologic scaffolds with and without a cellular component. , 2009, Biomaterials.

[15]  S. Badylak,et al.  Extracellular matrix for myocardial repair. , 2005, The heart surgery forum.

[16]  R. Oriol,et al.  CARBOHYDRATE ANTIGENS OF PIG TISSUES REACTING WITH HUMAN NATURAL ANTIBODIES AS POTENTIAL TARGETS FOR HYPERACUTE VASCULAR REJECTION IN PIG‐TO‐MAN ORGAN XENOTRANSPLANTATION1 , 1993, Transplantation.

[17]  U. Galili,et al.  Variations in activity of the human natural anti-Gal antibody in young and elderly populations. , 1995, The journals of gerontology. Series A, Biological sciences and medical sciences.

[18]  L. Valdes‐Cruz,et al.  Preliminary Experience With Cardiac Reconstruction Using Decellularized Porcine Extracellular Matrix Scaffold: Human Applications in Congenital Heart Disease , 2010, World journal for pediatric & congenital heart surgery.

[19]  W. Williams,et al.  Late risk of outcomes for adults with repaired tetralogy of Fallot from an inception cohort spanning four decades. , 2009, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[20]  N. Ratliff,et al.  Evidence for rejection of homograft cardiac valves in infants. , 1998, The Journal of thoracic and cardiovascular surgery.

[21]  Stephen F Badylak,et al.  Natural anti-galactose alpha1,3 galactose antibodies delay, but do not prevent the acceptance of extracellular matrix xenografts. , 2002, Transplant immunology.

[22]  C. Duran,et al.  Aortic Valve Replacement with Autologous Pericardium: Surgical Technique , 1995, Journal of cardiac surgery.

[23]  S. Badylak,et al.  Chemoattraction of progenitor cells by remodeling extracellular matrix scaffolds. , 2009, Tissue engineering. Part A.

[24]  R. Hetzer,et al.  European Contegra multicentre study: 7-year results after 165 valved bovine jugular vein graft implantations. , 2009, The Thoracic and cardiovascular surgeon.